K. Sobotta, MD

Articles by K. Sobotta, MD

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy

ByMichael Untch, MD, PhD,Franz Von Koch, MD,C. Crohns, MD,K. Sobotta, MD,Steffen Kahlert, MD,Gottfried E. Konecny, MD,H. Hepp, MD

May 1st 2001

Several attempts have been made to improve the survival rates of breast cancer patients. The benefit of adjuvant chemotherapy was clearly shown, but the absolute difference of 2% to 11% in overall survival, depending on the

Latest Updated Articles

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy
May 1st 2001

K. Sobotta, MD

Articles by K. Sobotta, MD

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Bridging the Gap: Overcoming Institutional Barriers to Exercise Oncology